The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis and immune modulation, addressing ...

(MENAFN- GlobeNewsWire - Nasdaq) The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis ...

The International Advisory Committee on Clinical Trials led a multinational panel updating the McDonald criteria, adding the optic nerve as a fifth anatomical location and allowing specific magnetic ...

Several factors were associated with increased pain among patients with systemic sclerosis, including the pain type, pain location, and disease subtype. Nearly all patients with systemic sclerosis ...

Christina Applegate knows her loved ones are navigating a difficult chapter. But while her teenager hasn’t outwardly expressed the difficulties with seeing her mother ill, the 53-year-old notices a ...

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of ...

Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally ...

Please provide your email address to receive an email when new articles are posted on . Mycophenolate mofetil outperformed methotrexate, steroids and other immunosuppressives in diffuse cutaneous SSc ...

Safety and efficacy of chimeric antigen receptor (CAR)–T cell therapy (BRG01) targeting the Epstein-Barr virus (EBV) envelope protein in EBV+ lymphoproliferative disease patients. Cumulative incidence ...

ABSTRACT: Background and Aims: Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by widespread fibrosis and vascular abnormalities that affect multiple organs, including the ...